Alnylam Elects Amy Schulman to its Board of Directors
News Jul 05, 2014
Alnylam Pharmaceuticals, Inc. has announced the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.
"Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "Given our robust clinical progress and our potential transition to a commercial company in the coming years, Amy's addition to our Board comes at an opportune time as we advance RNAi therapeutics to patients."
"I am excited to join the Board of Alnylam, a first-in-class innovation-based biotechnology company, and a pioneer in advancing an entirely new class of high impact medicines with RNAi therapeutics," said Ms. Schulman. "The tremendous progress Alnylam has made in its clinical efforts has yielded very encouraging results. I look forward to working with the outstanding team of management and directors in place today and contributing to the company's value creation strategy and execution."
Ms. Schulman originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth. In 2010, in addition to her role as General Counsel, Ms. Schulman became President and General Manager of Pfizer's $2.1 billion global infant formula and nutrition business. Once that business was sold to Nestlé she assumed responsibility for the Consumer Healthcare business.
Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm's mass tort and class-action practice. Ms. Schulman's accomplishments have earned her recognition from leading publications and organizations.
In 2013 Fortune magazine named her one of the "50 Most Powerful Women in Business." That same year, The American Lawyer named her one of the "Top 50 Innovators," and The National Law Journal named her one of "The 100 Most Influential Lawyers in America."
The American Bar Association honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of The Brookings Institution and Wesleyan University.
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
How Do Plants Avoid UV Damage?News
Public health warnings against too much exposure to UV are based on sound advice: UV rays can damage DNA and cause cancers and other diseases. Plants, however, cannot avoid UV. A new study now shows how plants' DNA repair system helps combat constant UV exposure.READ MORE
Comments | 0 ADD COMMENT
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018